{"id":62638,"date":"2026-02-12T10:06:02","date_gmt":"2026-02-12T09:06:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/"},"modified":"2026-02-12T10:06:02","modified_gmt":"2026-02-12T09:06:02","slug":"iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/","title":{"rendered":"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection"},"content":{"rendered":"
\n

\nEstablishes New Benchmark for High Identity Assurance Based on Accredited Testing of Industry Standard<\/p>\n

LONDON–(BUSINESS WIRE)–iProov<\/a>, the world’s leading provider of science-based biometric identity verification solutions, today announced that its Dynamic Liveness technology is the first and only solution to successfully achieve an Ingenium Level 4 evaluation and the CEN\/TS 18099 High technical specification for Injection Attack Detection, following an independent evaluation by the ISO\/IEC 17025-accredited, Ingenium<\/a> Biometric Laboratories. Ingenium Level 4 builds on the requirements outlined in CEN\/TS 18099, providing an increased level of assurance with an extended period of active testing and inclusion of complex, highly-weighted attack types.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAs AI-generated deepfakes and injection attacks rapidly evolve, CEN\/TS 18099 is helping organizations to move beyond vendor-led claims with accredited, standards-based benchmarks that provide real comparability and trust. While many biometric providers point to independent testing, too often these evaluations are conducted against proprietary frameworks that have not been developed by industry standards groups. As a result, the testing requirements are inconsistent and cannot be meaningfully compared across vendor solutions.<\/p>\n

\n\u201cIn the age of deepfakes, biometric security must be proven, not promised,\u201d said Andrew Bud, founder and CEO of iProov. \u201cCEN\/TS 18099 is the first true benchmark for injection attack detection, a requirement now included in NIST 800-63-4. Achieving Ingenium Level 4 through accredited testing sets iProov apart as the highest-assurance facial biometric provider independently validated today.\u201d<\/p>\n

\nDuring 40 days of intensive evaluation by Ingenium, no successful Injection Attack Method could be established, and iProov successfully blocked all attempts. Critically, this highest tier of protection was achieved while maintaining a Bona Fide Presentation Classification Error Rate (BPCER) of just 1.3%, demonstrating that statutory-grade resilience does not require sacrificing usability.<\/p>\n

\nCEN Level High represents a significant benchmark for injection attack detection under the CEN\/TS 18099 framework and provides organizations with a clear, accredited reference point when assessing biometric providers. Exceeding the CEN High level demonstrates that iProov is delivering a highly secure solution independently validated against one of the most demanding standards-based evaluations currently in the market.<\/p>\n

\nIngenium\u2019s Level 4 Injection Attack Detection evaluation establishes iProov among the leading benchmark solutions for organizations looking to align with the latest NIST 800-63-4 Digital Identity Guidelines<\/a> and provides a clear path for those requiring phishing-resistant, digital injection-aware security. By combining these results with FIDO Face Verification Certification, iProov provides the only independently established audit trail for the world\u2019s most demanding regulatory environments, including the UK National Cyber Plan<\/a> and the EU\u2019s EUDI Wallet frameworks<\/a>. Its solution also conforms to the Web Content Accessibility Guidelines<\/a> (WCAG) 2.2 Level AA, including Section 508, delivering an inclusive user experience while achieving high performance.<\/p>\n

\nFor further information on iProov\u2019s industry certifications, click here<\/a>.<\/p>\n

\nAbout iProov<\/b><\/p>\n

\niProov provides science-based biometric solutions that enable the world\u2019s most security-conscious organizations to streamline secure remote onboarding and authentication for digital and physical access. Its award-winning liveness technology and iSOC offer unmatched resilience against deepfakes and generative AI threats while ensuring effortless, scalable user experiences. Trusted by leading governments and enterprises, including the U.S. Department of Homeland Security, U.K. Home Office, GovTech Singapore, ING, and UBS, iProov sets the standard in biometric identity assurance. Learn more at www.iproov.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nLouise Burke
\n
Global PR Manager
\n
iProov
\n
Louise.burke@iproov.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Establishes New Benchmark for High Identity Assurance Based on Accredited Testing of Industry Standard LONDON–(BUSINESS WIRE)–iProov, the world’s leading provider of science-based biometric identity verification solutions, today announced that its Dynamic Liveness technology is the first and only solution to successfully achieve an Ingenium Level 4 evaluation and the CEN\/TS 18099 High technical specification for … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62638","6":"format-standard","7":"category-industry"},"yoast_head":"\niProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Establishes New Benchmark for High Identity Assurance Based on Accredited Testing of Industry Standard LONDON–(BUSINESS WIRE)–iProov, the world’s leading provider of science-based biometric identity verification solutions, today announced that its Dynamic Liveness technology is the first and only solution to successfully achieve an Ingenium Level 4 evaluation and the CEN\/TS 18099 High technical specification for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T09:06:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260212274042\/en\/2214606\/22\/Master_iProov_Logo_2024.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\\\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection\",\"datePublished\":\"2026-02-12T09:06:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/\"},\"wordCount\":565,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260212274042\\\/en\\\/2214606\\\/22\\\/Master_iProov_Logo_2024.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/\",\"name\":\"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\\\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260212274042\\\/en\\\/2214606\\\/22\\\/Master_iProov_Logo_2024.jpg\",\"datePublished\":\"2026-02-12T09:06:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260212274042\\\/en\\\/2214606\\\/22\\\/Master_iProov_Logo_2024.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260212274042\\\/en\\\/2214606\\\/22\\\/Master_iProov_Logo_2024.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\\\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/","og_locale":"en_US","og_type":"article","og_title":"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection - Pharma Trend","og_description":"Establishes New Benchmark for High Identity Assurance Based on Accredited Testing of Industry Standard LONDON–(BUSINESS WIRE)–iProov, the world’s leading provider of science-based biometric identity verification solutions, today announced that its Dynamic Liveness technology is the first and only solution to successfully achieve an Ingenium Level 4 evaluation and the CEN\/TS 18099 High technical specification for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-12T09:06:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260212274042\/en\/2214606\/22\/Master_iProov_Logo_2024.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection","datePublished":"2026-02-12T09:06:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/"},"wordCount":565,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260212274042\/en\/2214606\/22\/Master_iProov_Logo_2024.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/","url":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/","name":"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260212274042\/en\/2214606\/22\/Master_iProov_Logo_2024.jpg","datePublished":"2026-02-12T09:06:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260212274042\/en\/2214606\/22\/Master_iProov_Logo_2024.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260212274042\/en\/2214606\/22\/Master_iProov_Logo_2024.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iproov-dynamic-liveness-is-the-first-and-only-solution-to-achieve-cen-ts-18099-high-and-ingenium-level-4-for-injection-attack-detection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN\/TS 18099 High and Ingenium Level 4 for Injection Attack Detection"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62638"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62638\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}